Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 9/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 9/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17460404 | 0.85 | MAPT (0.53) | KCNQ3KCNQ2HPGDELANEALDH1A1 | |
| SCHEMBL17460381 | 0.84 | KCNQ3 (0.47) | KCNQ3KCNQ2ALDH1A1APOBEC3AGAA | |
| SCHEMBL17468719 | 0.84 | PDE4B (0.52) | KCNQ3KCNQ2HPGDALDH1A1NPC1 | |
| SCHEMBL17468695 | 0.79 | PDE4B (0.56) | KCNQ3KCNQ2ALDH1A1GAAATM | |
| SCHEMBL17460410 | 0.78 | KCNQ3 (0.60) | KCNQ3KCNQ2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17460369 | 0.77 | PDE4B (0.59) | KCNQ3KCNQ2 | |
| SCHEMBL17460368 | 0.77 | KCNQ3 (0.62) | KCNQ3KCNQ2RAB9A | |
| SCHEMBL17468588 | 0.76 | PDE4B (0.54) | KCNQ3KCNQ2HPGDALDH1A1GAA | |
| SCHEMBL17468740 | 0.75 | PDE4B (0.55) | KCNQ3KCNQ2HPGDALDH1A1GAA | |
| SCHEMBL17460387 | 0.75 | JAK2 (0.45) | KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131669-B2 | Pyrazolopyrimidine compounds | PFIZER INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | PFIZER INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | PFIZER INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | PFIZER INC. (US) | 2017-07-20 | — | — | US | disclosed |
| EP-3172210-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | Pfizer Inc (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016012896-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012896-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131669-B2 | Pyrazolopyrimidine compounds | PDE4B, PDE4A, PDE7A | KCNQ3 1024/4885KCNQ2 1231/4885HPGD 954/4885 |
| US-20170204099-A1 | Pyrazolopyrimidine Compounds | DPYD, QDPR, ABCG2 | KCNQ3 50/4885KCNQ2 49/4885HPGD 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.